Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

(2019) Omar Mamlouk et al.   Journal for ImmunoTherapy of Cancer

AKI in Patients Receiving Immune Checkpoint Inhibitors

(2019) Mark A. Perazella et al.   Clinical Journal of the American Society of Nephrology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

(2018) Mark A. Perazella et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report

(2018) Ryo Koda et al.   BMC Nephrology

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis

(2018) Gema Fernandez-Juarez et al.   Clinical Journal of the American Society of Nephrology

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

(2017) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

(2016) Anushree C. Shirali et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

(2016) Frank B. Cortazar et al.   KIDNEY INTERNATIONAL

Kinetic eGFR and Novel AKI Biomarkers to Predict Renal Recovery

(2015) A. Dewitte et al.   Clinical Journal of the American Society of Nephrology

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biopsy-Proven Acute Interstitial Nephritis, 1993-2011: A Case Series

(2014) Angela K. Muriithi et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use

(2014) Mei-Ling Blank et al.   KIDNEY INTERNATIONAL

Association between AKI, Recovery of Renal Function, and Long-Term Outcomes after Hospital Discharge

(2012) N. Pannu et al.   Clinical Journal of the American Society of Nephrology

Notice

(2012)   Kidney International Supplements

Chronic Kidney Disease: An Inherent Risk Factor for Acute Kidney Injury?

(2010) P. Singh et al.   Clinical Journal of the American Society of Nephrology

Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury

(2008) S. S. Waikar et al.   Clinical Journal of the American Society of Nephrology

Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis

(2008) E. González et al.   KIDNEY INTERNATIONAL